Humana (HUM) Stock Forecast, Price & News

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Humana in the last year. There are currently 4 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HUM shares.
View HUM analyst ratings or view top-rated stocks.

16 Wall Street research analysts have issued 1 year price objectives for Humana's stock. Their HUM share price forecasts range from $540.00 to $652.00. On average, they expect the company's share price to reach $594.53 in the next year. This suggests a possible upside of 20.0% from the stock's current price.
View analysts price targets for HUM or view top-rated stocks among Wall Street analysts.

Humana's stock was trading at $512.19 at the beginning of 2023. Since then, HUM stock has decreased by 3.3% and is now trading at $495.27.
View the best growth stocks for 2023 here.

Humana saw a decrease in short interest during the month of August. As of August 15th, there was short interest totaling 2,780,000 shares, a decrease of 9.2% from the July 31st total of 3,060,000 shares. Based on an average daily volume of 1,470,000 shares, the short-interest ratio is presently 1.9 days. Currently, 2.3% of the shares of the company are sold short.
View Humana's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our HUM earnings forecast.

Humana Inc. (NYSE:HUM) posted its earnings results on Wednesday, August, 2nd. The insurance provider reported $8.94 EPS for the quarter, topping analysts' consensus estimates of $8.88 by $0.06. The insurance provider had revenue of $26.75 billion for the quarter, compared to analyst estimates of $25.83 billion. Humana had a trailing twelve-month return on equity of 20.70% and a net margin of 3.42%. Humana's revenue for the quarter was up 13.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $8.67 EPS.
Read the conference call transcript.

Humana announced a quarterly dividend on Thursday, August 17th. Stockholders of record on Friday, September 29th will be given a dividend of $0.885 per share on Friday, October 27th. This represents a $3.54 dividend on an annualized basis and a yield of 0.71%. The ex-dividend date is Thursday, September 28th.
Read our dividend analysis for HUM.

ETFs with the largest weight of Humana (NYSE:HUM) stock in their portfolio include Optimize AI Smart Sentiment Event-Driven ETF (OAIE), iShares U.S. Healthcare Providers ETF (IHF), Hennessy Stance ESG Large Cap ETF (STNC), First Trust Long/Short Equity ETF (FTLS), Fidelity Disruptive Medicine ETF (FMED), Alpha Intelligent - Large Cap Value ETF (AILV), First Trust Growth Strength ETF (FTGS) and American Customer Satisfaction ETF (ACSI).

Humana (NYSE:HUM) pays an annual dividend of $3.54 per share and currently has a dividend yield of 0.72%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 13.21%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, HUM will have a dividend payout ratio of 11.03% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for HUM.

Humana updated its FY 2023 earnings guidance on Sunday, September, 24th. The company provided EPS guidance of $28.25- for the period, compared to the consensus estimate of $28.29. The company issued revenue guidance of -.

1,597 employees have rated Humana Chief Executive Officer Bruce D. Broussard on Glassdoor.com. Bruce D. Broussard has an approval rating of 87% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Humana investors own include UnitedHealth Group (UNH), NVIDIA (NVDA), Walt Disney (DIS), Visa (V), Mastercard (MA), Alibaba Group (BABA), Boeing (BA), Salesforce (CRM), Johnson & Johnson (JNJ) and JPMorgan Chase & Co. (JPM).

Humana trades on the New York Stock Exchange (NYSE) under the ticker symbol "HUM."

Humana's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Bank Julius Baer & Co. Ltd Zurich (10.60%), State Street Corp (4.72%), Capital International Investors (3.12%), Capital World Investors (1.87%), Geode Capital Management LLC (1.85%) and Capital Research Global Investors (1.22%). Insiders that own company stock include Bruce D Broussard, Christopher H Hunter, David A Jr/Ky Jones, David A Jr/Ky Jones, Jorge S Mesquita, Joseph C Ventura, Samir Deshpande, Susan M Diamond, Timothy Alan Wheatley, Timothy S Huval and William Kevin Fleming.
View institutional ownership trends.

Shares of HUM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HUM stock can currently be purchased for approximately $495.27.

Humana (NYSE:HUM) has a market capitalization of $61.37 billion and generates $92.87 billion in revenue each year. The insurance provider earns $2.81 billion in net income (profit) each year or $26.80 on an earnings per share basis.

The company employs 67,100 workers across the globe.

Humana's mailing address is 500 West Main Street, LOUISVILLE KY, 40202. The official website for the company is www.humana.com. The insurance provider can be reached via phone at (502) 580-1000, via email at amysmith@humana.com, or via fax at 502-580-3639.